Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib 400 mg versus 800 mg in newly diagnosed chronic-phase chronic myeloid leukemia
2005-000657-29Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imatinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Novartis. Primary endpoint: Primary molecular response rate at 12 months. Started Jun 2005; status: completed.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2005-000657-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000657-29.